RxDoctor Payments Data

Gautam Gadey, MD

Interventional Cardiology · Burlington, MANPI 1134354962

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Edwards Lifesciences at 57.7% of the total. That places this record below the midpoint for interventional cardiology clinicians in MA, where the typical reported total is $3,030.

$2,417in general payments, 2019–2025

Across 30 payments — averaging $80.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Abbott$486
  • Boston Scientific$209
  • Cardiovascular Systems Inc.$173
  • Medtronic$135
  • Cardiva Medical, Inc.$19
$57,497in research payments, 2019–2025

Across 17 payments — averaging $3382.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$31K
  • Siemens Medical Solutions USA, Inc.$17K
  • Cardiovascular Systems Inc.$9K

What the payments were for

  • Food & beverage$2,417100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,417 in reported general payments places this provider in the 45th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$193,792
Medicare patients
372
Services billed
805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate18$313
Atorvastatin Calcium14$227

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Burlington

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →